Abstract
5. In this study, we used a colorimeter to accurately and objectively evaluate the efficacy and adverse effects of the QSNL (535 nm) laser for the treatment of solar lentigo. Twenty Korean volunteers with solar lentigines on the face were enrolled. Informed consent was obtained from the participants, and this clinical study was approved by the local institutional review board. We selected two prominent solar lentigines in each patient, and each patient received two sessions of 535 nm QSNL (Pastelle; WONTECH Co., Ltd., Daejeon, Korea) therapy at 4-week intervals. An additional 4-week followup period was conducted after the last treatment. All lentigines were treated with pulses of QSNL irradiation (20 ns pulse width, 0.7∼0.8 J/cm 2 energy, and 3∼4 mm
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
